Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Viticks is a topical insect repellent spray developed and marketed by HENNIG ARZNEIMITTEL. The product's active ingredient is icaridin (also known as picaridin) at a concentration of 15%. Unlike insecticides that kill insects, Viticks functions as a repellent by creating a protective scent barrier on the skin or clothing that deters blood-sucking insects. It is designed to provide protection against a wide range of insects, including mosquitoes (such as malaria, yellow fever, and tiger mosquitoes), ticks, horseflies, and grass mites. Viticks offers protection lasting up to 8 hours against mosquitoes and horseflies, and up to 6 hours against ticks. The spray features a 360-degree application system and is approved for use in adults and children aged 2 years and older.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Viticks.